53568-11-9

Upstream product

• 83781-72-0 3-carbomethoxy-5-methoxy-1,2,3,4-tetrahydronaphthalene 
• 135-02-4 ortho-anisaldehyde 
• 32298-34-3 (2-methoxy benzyl) succinic acid 
• 1144-98-5 2-(2-Methoxy-benzyliden)-bernsteinsaeure 
• 16035-97-5 5-Methoxy-3-carboxy-tetralon-⁽¹⁾ 
• 32178-63-5 8-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 
• 1267318-78-4 C₁₂H₁₄O₄ 

Downstream Products

• 827022-92-4 8-hydroxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid (4-diethylamino-phenyl)-amide 

Relevant academic research and scientific papers

Benzoxaborole antimalarial agents. Part 2: Discovery of fluoro-substituted 7-(2-carboxyethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles

A series of new boron-containing benzoxaborole compounds was designed and synthesized for a continuing structure-activity relationship (SAR) investigation to assess the antimalarial activity changes derived from side-chain structural variation, substituent modification on the benzene ring and removal of boron from five-membered oxaborole ring. This SAR study demonstrated that boron is required for the antimalarial activity, and discovered that three fluoro-substituted 7-(2-carboxyethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles (9, 14 and 20) have excellent potencies (IC50 0.026-0.209 μM) against Plasmodium falciparum.

TETRALINE DERIVATIVES AS GHRELIN RECEPTOR MODULATORS

The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.